DIRS.INFO The most relevant business & tech news

Sept 26 (Reuters) - Shares of Immunovant (IMVT.O) surged nearly 80% on Tuesday, after early-stage data from its experimental antibody treatment exceeded analysts' expectations. Immunovant is developing its antibody drug, IMVT-1402, as an under-the-skin injection to potentially treat autoimmune diseases. Immunovant's experimental drug reduced the levels of IgG, or immunoglobulin antibodies, that cause inflammation and disease in healthy adults. Shares of Roivant Sciences (ROIV.O), Immunovant's largest shareholder with a 56.5% stake, according to LSEG data, also rose 17.5% to $12. The positive data from IMVT-1402 could give Roivant another "potentially blockbuster" candidate to transact, after its experimental treatment for bowel disease, Jefferies analyst Dennis Ding said.

Persons: J.P, Morgan, Brian Cheng, drugmakers Johnson, Johnson, Hytrulo, Immunovant, transact, Jefferies, Dennis Ding, Bhanvi, Krishna Chandra Organizations: UCB, Roivant Sciences, Thomson Locations: United States, York, IMVT, Bengaluru

REUTERS/Brendan McDermid/File Photo/File Photo Acquire Licensing RightsAug 25 (Reuters) - AstraZeneca (AZN.L) said on Friday it has sued the U.S. government to block parts of a program that gives the Medicare health insurance plan the power to negotiate lower drug prices. The program faces at least seven other court challenges, including from leading industry group PhRMA and drugmakers Johnson & Johnson (JNJ.N), Merck & Co (MRK.N), Bristol Myers Squibb (BMY.N) and privately-held Boehringer Ingelheim. The drug price negotiation program is part of President Joe Biden's signature Inflation Reduction Act (IRA). ‍AstraZeneca said the program would deter continued development of treatments such as its cancer drug Lynparza and rare blood disorder drug Soliris, which carry orphan drug status for multiple conditions. An HHS spokesperson said in a statement that the agency "will vigorously defend the President's drug price negotiation law, which is already helping to lower healthcare costs for seniors and people with disabilities."

Persons: Brendan McDermid, drugmakers Johnson, Johnson, Joe Biden's, AstraZeneca, Bhanvi, Dhanya Ann Thoppil, Shilpi Majumdar Organizations: AstraZeneca, New York Stock Exchange, REUTERS, U.S, Merck & Co, Bristol Myers Squibb, U.S . Department of Health, Human Services, Thomson Locations: British, Delaware, United States, U.S, Bengaluru

State and local officials have touted the settlements as providing desperately needed relief to communities hit hard by the crisis. But when the money will be paid out, and who will get it, remains far from clear, Reuters has found. Among the states where money is already reaching organizations on the ground are Massachusetts, Kentucky and Arizona. Most states share a significant portion of their total settlement funds with their city and county governments, which make their own independent decisions about how to spend. But in May, the board overseeing the state’s opioid settlement denied a joint application by Challenges and a county health department to fund harm reduction efforts, without explaining its decision.

Persons: Johnson, ”, Brandon Marshall, Julie Burns, Chris Bryan, Glenn Hegar, Lisa Ruzicka, “, Ruzicka, “ I’ve, drugmakers Johnson, Lauren Kestner, Tricia Christensen, –, we’re, ” Marc Burrows, Brendan Pierson, Disha, Alexia Garamfalvi, Claudia Parsons Organizations: Johnson, U.S . Centers for Disease Control, Reuters, District of Columbia, Reuters Graphics Reuters Graphics Reuters, Brown University School of Public Health, Rhode, Texas, Hope Foundation, Walgreens, Alliance, state’s Department of Health, Human Services, Prevention Services, Community Education Group, Alabama Attorney, University of Mississippi Medical, Inc, Thomson, & $ Locations: Massachusetts, Texas, United States, Maryland, Illinois, . Arkansas, Kentucky, Arizona, Rhode, RIZE Massachusetts, RIZE, Kansas, North Carolina, Charlotte, Appalachia, Mississippi, Alabama, New York

Search resuls for: "drugmakers Johnson"

3 mentions found